Proteomic Identification of NAF Biomarkers

NAF 生物标志物的蛋白质组学鉴定

• 批准号: 6898798
• 负责人: RICHARD C ZANGAR
• 金额: $ 40.63万
• 依托单位: BATTELLE PACIFIC NORTHWEST LABORATORIES
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-06-01 至 2007-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6898798
• 关键词: biomarker; breast neoplasm /cancer diagnosis; breast neoplasms; cancer risk; clinical research; early diagnosis; female; human middle age (35-64); human subject; mass spectrometry; proteomics; questionnaires; women' s health

DESCRIPTION (provided by applicant): Breast cancer is responsible for ~43,000 deaths per year, a number which could be reduced dramatically by early detection of the disease. Currently, detection of breast cancer relies primarily on physical examination and conventional mammography. While these procedures have improved early detection of breast cancer and thereby decreased mortality, they still result in relatively high rates of false-positive and false-negative diagnoses. In addition, breast cancer prognosis is based on histological examination and is inadequate for assessing micrometastases. Due to this inability to accurately predict the risk of recurrence, 50% or more of breast cancer patients are unnecessarily treated with adjuvant therapy. A more useful and accurate evaluation of breast cancer could be obtained if these current, observation-based methods were supplemented with a molecular assessment. A number of serum proteins are reported to be altered in individuals with breast cancer when compared with healthy individuals. There is not, however, any known circulating protein that is suitable to define the stage of breast cancer or as a general marker for breast cancer, especially in the early stages of this disease. Mammary ductal cells are the cellular origin for 70% to 80% of breast cancer cases. Nipple aspirate fluid (NAF), which is obtained from non-lactating women, contains proteins secreted directly by these ductal cells. As such, we hypothesize that NAF is a concentrated and selective source of protein biomarkers for breast cancer. Proteomic approaches offer an unbiased way to evaluate NAF as a source of biomarkers and is sufficiently sensitive for small NAF volumes (10 to 50 (l). Therefore, the goals of this proposal are to characterize the proteome of NAF and to undertake preliminary analyses to identify potential protein biomarkers. To accomplish these goals, we propose to undertaken the following specific aims: Aim #1. Characterize the Proteome of Pooled NAFs Using Mass Spectrometry. Aim #2. Identify Potential Protein Biomarkers in Individual NAF Samples from Women with Early-Stage Breast Cancer using Isotopic Labeling and Mass Spectrometry. Upon completion of these aims, we will have provided the first detailed characterization of the NAF proteome and identified a subset of NAF proteins that are potential markers of breast disease.

描述（由申请人提供）：乳腺癌每年导致约43，000人死亡，通过早期发现该疾病可以大幅减少这一数字。目前，乳腺癌的检测主要依赖于身体检查和传统的乳房X光检查。虽然这些程序改善了乳腺癌的早期检测，从而降低了死亡率，但它们仍然导致相对较高的假阳性和假阴性诊断率。此外，乳腺癌预后是基于组织学检查，是不足以评估微转移。由于无法准确预测复发风险，50%或更多的乳腺癌患者不必要地接受辅助治疗。如果这些目前基于观察的方法辅以分子评估，则可以获得更有用和更准确的乳腺癌评估。据报道，与健康个体相比，乳腺癌患者的许多血清蛋白质发生了变化。然而，没有任何已知的循环蛋白适合于定义乳腺癌的阶段或作为乳腺癌的一般标志物，特别是在这种疾病的早期阶段。乳腺导管细胞是70%至80%乳腺癌病例的细胞来源。乳头抽吸液（NAF），这是从非哺乳期妇女获得，含有这些导管细胞直接分泌的蛋白质。因此，我们假设NAF是乳腺癌蛋白质生物标志物的浓缩和选择性来源。蛋白质组学方法提供了一种公正的方法来评估NAF作为生物标志物的来源，并且对于小NAF体积（10至50（l））足够敏感。因此，本提案的目标是表征NAF的蛋白质组，并进行初步分析，以确定潜在的蛋白质生物标志物。为了实现这些目标，我们提出了以下具体目标：目标#1。使用质谱法表征合并的NAF的蛋白质组。 目标2。使用同位素标记和质谱法鉴定早期乳腺癌妇女个体NAF样本中潜在的蛋白质生物标志物。 在完成这些目标后，我们将提供NAF蛋白质组的第一个详细特征，并确定了一个NAF蛋白的子集，是乳腺疾病的潜在标志物。

项目成果

Studying cellular processes and detecting disease with protein microarrays.

使用蛋白质微阵列研究细胞过程并检测疾病。

• DOI: 10.1080/03602530500205309
• 发表时间: 2005
• 期刊: Drug metabolism reviews.
• 作者: Zangar,RichardC;Varnum,SusanM;Bollinger,Nikki
• 通讯作者: Bollinger,Nikki